18 F-DCFPyL PET/CT allowed for the detection of sites of urothelial carcinoma, albeit with low levels of radiotracer uptake. Analysis of RNA-sequencing data revealed that bladder cancer had significantly lower levels of PSMA expression than both prostate cancer and clear cell renal cell carcinoma. Consistent with this observation, immunohistochemical staining of tissue from one of the imaged patients demonstrated a low level of neovascularization and nearly absent PSMA expression. Conclusion The relatively scant expression of PSMA by urothelial carcinoma likely limits the utility of PSMAtargeted PET imaging of this malignancy. Future research efforts should focus on the development of other molecularly targeted imaging agents for urothelial carcinoma.
Introduction
At the present time, the mainstays of imaging for urothelial carcinoma of bladder and upper urinary tract are computed tomography (CT) and magnetic resonance imaging (MRI) [1] . These imaging modalities, however, are limited in their ability to detect sub-centimeter sites of metastatic disease. This is evident by the fact that upwards of 20% of patients with clinically localized urothelial carcinoma of the bladder will be found to have positive lymph nodes at the time of radical cystectomy [2] . As an adjunct to CT and MRI, positron emission tomography (PET) using the metabolic radiotracer 2-deoxy-2-[ 
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test has shown only modest improvements in the ability to detect small volume sites of disease [3] [4] [5] [6] .
Owing to the limitations of currently available modalities for imaging urothelial carcinoma, there has been growing interest in the development of molecularly targeted imaging agents for this disease. One molecular target of particular promise is the type II glycoprotein known as prostate-specific membrane antigen (PSMA), which despite the specificity implied by its name is highly expressed in the neovasculature of a number of solid malignancies including urothelial carcinoma [7] [8] [9] [10] . PSMA-targeted PET imaging has been widely studied in men with prostate cancer (reviewed in [11] ) and more recently has been explored in other malignancies [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Among these cancers, clear cell renal cell carcinoma is the most well studied and initial reports suggest that PET/CT utilizing PSMA-targeted radiotracers may detect metastatic lesions with higher sensitivity than CT, MRI, and 18 F-FDG PET/CT [12] [13] [14] [15] [16] . Additionally, PSMAtargeted imaging has been shown to have potential for the detection of other solid malignancies including cancers of the bone [17] , brain [18] , breast [19] , gastrointestinal tract [20] , liver [21] and thyroid [22] .
Early studies utilizing the radiolabeled J591 antibody have demonstrated initial feasibility of imaging urothelial carcinoma using PSMA-targeted agents [23, 24] . More recently, a case report was published on the successful imaging of a patient with metastatic upper tract urothelial carcinoma using the urea-based small molecule inhibitor of PSMA known as 68 Ga-PSMA-11 (also known as 68 Ga-PSMA-HBED-CC) [25] . While 68 Ga-PSMA-11 is the most widely utilized agent for PSMA-targeted PET imaging, a handful of other radiotracers have been developed including 18 F-DCFPyL [26] [27] [28] . Available data suggest that PET imaging with 18 F-DCFPyL may offer improved image quality and lesion detection compared to the 68 Ga-PSMA-11 radiotracer [29, 30] .
Herein, we present data from three patients with metastatic urothelial carcinoma imaged with 18 F-DCFPyL PET/ CT. Although this imaging test allowed for the detection of sites of urothelial carcinoma, only modest levels of radiotracer uptake were observed. Our findings suggest that PSMA-targeted PET likely does not afford improved sensitivity over conventional modalities for imaging this malignancy.
Patients and methods
Three patients with metastatic urothelial carcinoma were imaged with 18 F-DCFPyL PET/CT as previously described by Rowe et al. [12] . Patients were imaged following enrollment in an institutional review board-approved clinical study investigating the utility of this imaging test in patients with non-prostate epithelial malignancies. In brief, 1 h after intravenous administration of ~ 9 mCi of the 18 F-DCFPyL radiotracer, a PET/CT was acquired from the mid-thigh to the vertex of the skull. To decrease bladder activity, patients were asked to void prior to imaging. Acquired images were reviewed by a single radiologist with extensive experience in interpreting 18 F-DCFPyL PET/ CT studies (S.P.R.). Any lesion with perceptible radiotracer uptake above background was considered positive. Lean body mass corrected maximum standardized uptake values (SUV max ,) were recorded for each detected lesion and findings on 18 F-DCFPyL PET/CT were compared to those on contemporaneously acquired conventional imaging studies.
To more broadly explore PSMA as a molecular target of urothelial carcinoma, RNA-sequencing data from The Cancer Genome Atlas was used to compare the relative expression of FOLH1 (the gene that encodes the PSMA protein) among cases of bladder cancer, prostate cancer, and clear cell renal cell carcinoma. RNA-sequencing data were obtained from the Broad Institute Genome Data Analysis Center (http://firebrowse.org) with transcript quantification having already been performed using RNA-sequencing by expectation maximization (RSEM) [31] . Log-transformed normalized RSEM values [32] for each cancer type were compared using the Kruskal-Wallis test. Statistical analysis was performed with Stata 13.1 (StataCorp, College Station, TX). A two-tailed P < 0.05 was defined as statistical significance. To further expand upon this analysis, immunohistochemistry was performed on a biopsy specimen from one of the imaged patients (patient 1) using antibodies against PSMA and the endothelial cell marker CD34. For comparison, tissue from two additional patients, one with prostate cancer and the second with clear cell renal cell carcinoma, were also stained.
Results
The characteristics of the three imaged patients are provided in Table 1 .
The first patient had a history of metastatic urothelial carcinoma of the bladder treated with gemcitabine/cisplatin followed by atezolizumab. On surveillance imaging the patient was noted to have a recurrent lesion of the prostatic urethra. This lesion was visible on both pelvic MRI and 18 F-FDG PET/CT with an SUV max of 9.0 (Fig. 1) . This lesion had no discernable uptake above background with 18 F-DCFPyL. The second patient presented with a tumor of the bladder as well as extensive pelvic lymph node involvement. Imaging was performed prior to administration of systemic therapy. Both the bladder mass and adenopathy were visible on contrast-enhanced CT (Fig. 2) . On 18 F-DCFPyL PET/CT, these lesions demonstrated only modest radiotracer uptake with SUV max in the range of 2.0-2.5.
The third patient had a history of metastatic urothelial carcinoma of the right renal pelvis treated with nephroureterectomy and gemcitabine/cisplatin. On conventional imaging, the patient was noted to have an enlarged aortocaval lymph node measuring 2.2 cm and a 1.2 cm right lower lobe lung metastasis. The patient's lymph node was visible on 18 F-FDG PET/CT with an SUV max of 5.7 (Fig. 3) . This lesion was also identifiable on 18 F-DCFPyL PET/CT, albeit with a lower SUV max value of 3.1. The patient's lung lesion was visible with both imaging modalities; however, 18 F-FDG PET/CT provided for superior image quality and a higher SUV max relative to 18 F-DCFPyL (4.6 versus 1.5).
Comparison of gene expression levels utilizing RNAsequencing data demonstrated that bladder cancer had significantly lower levels of FOLH1 gene expression than both prostate cancer and clear cell renal cell carcinoma (Fig. 4) . Moreover, immunohistochemical staining of the tumor specimen from patient 1 demonstrated scant neovascularization and almost no detectable PSMA expression (Fig. 5 ). In contrast, staining for PSMA was abundant in the prostate cancer and renal cell carcinoma specimens. In the case of prostate cancer, PSMA expression was present on the epithelial cells of the tumor, whereas in the case of clear cell renal cell carcinoma, the expression was restricted to the endothelial cells of the tumor neovasculature.
Discussion
In the presented series of three patients, PSMA-targeted PET imaging using the 18 F-DCFPyL radiotracer allowed for the detection of foci of urothelial carcinoma across a range of anatomic sites including the bladder, lymph nodes, and lung. The degree of radiotracer uptake, however, was universally low and less than that with 18 F-FDG in the two patients with available contemporaneous imaging. As evident by RNA-sequencing data and immunohistochemical staining, the poor performance of 18 F-DCFPyL PET/CT for imaging urothelial cancer is likely explained by scant tumor neovascularization and low associated levels of PSMA expression.
A major limitation of this study is the small sample size of only three patients. While these patients may not be representative of the larger population of individuals with urothelial cancer, our analysis of RNA-sequencing data from The Cancer Genome Atlas suggests that the average expression of PSMA is low across this malignancy.
In conclusion, PSMA-targeted 18 F-DCFPyL PET/CT is likely of limited clinical value for imaging patients with urothelial carcinoma. This can be explained by low levels of target PSMA expression within the tumor neovasculature. Future research efforts should focus on the development of other molecularly targeted imaging agents for this disease. 
